Tasosartan

Tasosartan

Gene therapy
Clinical data
ATC code	C09CA05 (WHO)
Physiological data
Legal status
Pharmacokinetic data
Identifiers
IUPAC name 2,4-dimethyl-8-[ [4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[6,5-d]pyrimidin-7-one
PubChem Template:Abbreviation	60919
Chemical and physical data
Formula	C23H21N7O
Molar mass	411.459 g/mol

WikiDoc Resources for Tasosartan
Articles
Most recent articles on Tasosartan Most cited articles on Tasosartan Review articles on Tasosartan Articles on Tasosartan in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Tasosartan Images of Tasosartan Photos of Tasosartan Podcasts & MP3s on Tasosartan Videos on Tasosartan
Evidence Based Medicine
Cochrane Collaboration on Tasosartan Bandolier on Tasosartan TRIP on Tasosartan
Clinical Trials
Ongoing Trials on Tasosartan at Clinical Trials.gov Trial results on Tasosartan Clinical Trials on Tasosartan at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Tasosartan NICE Guidance on Tasosartan NHS PRODIGY Guidance FDA on Tasosartan CDC on Tasosartan
Books
Books on Tasosartan
News
Tasosartan in the news Be alerted to news on Tasosartan News trends on Tasosartan
Commentary
Blogs on Tasosartan
Definitions
Definitions of Tasosartan
Patient Resources / Community
Patient resources on Tasosartan Discussion groups on Tasosartan Patient Handouts on Tasosartan Directions to Hospitals Treating Tasosartan Risk calculators and risk factors for Tasosartan
Healthcare Provider Resources
Symptoms of Tasosartan Causes & Risk Factors for Tasosartan Diagnostic studies for Tasosartan Treatment of Tasosartan
Continuing Medical Education (CME)
CME Programs on Tasosartan
International
Tasosartan en Espanol Tasosartan en Francais
Business
Tasosartan in the Marketplace Patents on Tasosartan
Experimental / Informatics
List of terms related to Tasosartan

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tasosartan is an angiotensin II receptor antagonist.

It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.